Webinar Home Page
Personalized Therapies and Best Clinical Practices for Lung Cancer
2016
Click below to view
H. Jack West, MD Riely Gregory
Webinar #1150a
DEBATE 1: Next Generation Sequencing (NGS) testing is achieving its promise to help us devise better therapeutic strategies for our NSCLC patients?
.2 hours
H. Jack West, MD vs. Gregory J. Riely, MD, PhD
January 4, 2016 – January 4, 2017
Joel W. Neal, MD, PhD
Webinar #1150b
Stage I - III NSCLC: An update on clinical trials and treatment strategies for early-stage NSCLC. How do we manage early-stage NSCLC if NGS reveals an actionable mutation, e.g. EGFR, ALK?
.2 hours
Joel W. Neal, MD, PhD
January 4, 2016 – January 4, 2017
Philip D. Bonomi, MD
Webinar #1150c
Managing weight loss in patients with advanced NSCLC
.2 hours
Philip D. Bonomi, MD
January 4, 2016 – January 4, 2017
Paul A. Bunn, Jr., MD
Webinar #1150d
Squamous NSCLC - The new landscape: How do we select optimal therapies from an expanding list of new and novel options: First line? Refractory patients? Maintenance therapy?
.2 hours
Paul A. Bunn, Jr., MD
January 4, 2016 – January 4, 2017
Suresh S. Ramalingam, MD
Webinar #1150e
Emerging options in late-stage development for rare NSCLC mutations: Inhibitors of KRAS? CDK4/CDK6 for KRAS mutants? Selumetinib? HSP90? RET Fusions? ROS 1? BRAF? HER2? Etc.?
.2 hours
Suresh S. Ramalingam, MD
January 4, 2016 – January 4, 2017
Moderator: Paul A. Bunn, Jr., MD
Webinar #1150f
Expert Panel Discussion, Q&A
.2 hours
Moderator: Paul A. Bunn, Jr., MD
January 4, 2016 – January 4, 2017
Roy S. Herbst, MD, PhD
Webinar #1150g
Why is Immune therapy so different from targeted and chemotherapy for lung cancer?
.2 hours
Roy S. Herbst, MD, PhD
January 4, 2016 – January 4, 2017
H. Jack West, MD
Webinar #1150h
Anti-PD-1 therapy for squamous NSCLC after two years of therapy: One patient's experience
.2 hours
H. Jack West, MD
January 4, 2016 – January 4, 2017
Edward B. Garon, MD
Webinar #1150i
Clinical endpoints for PD-1/PD-L1 immunotherapies in NSCLC: What are the best endpoints to measure efficacy? Are response rates and survival still useful clinical endpoints? Do we fully understand pseudoprogression and other unique patterns of response to immunotherapy?
.2 hours
Edward B. Garon, MD
January 4, 2016 – January 4, 2017
Moderator: Roy S. Herbst, MD, PhD
Webinar #1150j
Expert Panel Discussion and Q&A
.2 hours
Moderator: Roy S. Herbst, MD, PhD
January 4, 2016 – January 4, 2017
Heather A. Wakelee, MD
Webinar #1150k
First-line checkpoint inhibition immunotherapy for NSCLC patients with advanced lung cancer: What are the barriers for immune therapy to become a first-line treatment option?
.2 hours
Heather A. Wakelee, MD
January 4, 2016 – January 4, 2017
David R. Spigel, MD
Webinar #1150l
Treatment after immune-therapy for squamous and nonsquamous NSCLC: What do you use for patients who fail to respond to nivolumab: Ramucirumab? Docetaxel? Another PD-1 MAb or a PD-L1 MAb? Combine immune therapies? Clinical trial w/ another investigational agent?
.2 hours
David R. Spigel, MD
January 4, 2016 – January 4, 2017
Edward B. Garon, MD Heather A. Wakelee, MD
Webinar #1150m
DEBATE 2: PD-L1 is a reliable biomarker for use in deciding to use a checkpoint inhibitor for patients with NSCLC.
.2 hours
Edward B. Garon, MD vs. Heather A. Wakelee, MD
January 4, 2016 – January 4, 2017
David R. Spigel, MD
Webinar #1150n
What are the differences between targeting PD-1 and the PD-1 Ligand? Are these immune checkpoint antibodies interchangeable? Should they be used in different selected populations?
.2 hours
David R. Spigel, MD
January 4, 2016 – January 4, 2017
Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Webinar #1150o
Managing and preventing immune-related side effects with checkpoint inhibition: What have we learned and how can we better help our patients?
.2 hours
Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
January 4, 2016 – January 4, 2017
Moderator: Roy S. Herbst, MD, PhD
Webinar #1150p
Expert Panel Discussion and Q&A
.2 hours
Moderator: Roy S. Herbst, MD, PhD
January 4, 2016 – January 4, 2017
Gregory J. Riely, MD, PhD
Webinar #1150q
Exon 19 deletion and Exon 21 mutation: Does the type of EGFR mutation matter for therapy selection?
.2 hours
Gregory J. Riely, MD, PhD
January 4, 2016 – January 4, 2017
H. Jack West, MD
Webinar #1150r
Is the Optimal Therapy for Advanced NSCLC with an Activating EGFR Mutation a Combination?
.2 hours
H. Jack West, MD
January 4, 2016 – January 4, 2017
Gregory J. Riely, MD, PhD
Webinar #1150s
Strategies for managing acquired resistance to anti-EGFR therapy: An update on options for treatment, biopsies (including liquid and repeat) & managing CNS involvement
.2 hours
Gregory J. Riely, MD, PhD
January 4, 2016 – January 4, 2017
Moderator: H. Jack West, MD
Webinar #1150t
Expert Panel Discussion and Q&A
.2 hours
Moderator: H. Jack West, MD
January 4, 2016 – January 4, 2017
Robert C. Doebele, MD, PhD
Webinar #1150u
The changing ALK Landscape: Integrating second-line therapies into initial therapy and managing patents with CNS involvement
.2 hours
Robert C. Doebele, MD, PhD
January 4, 2016 – January 4, 2017
Roy S. Herbst, MD, PhD Robert C. Doebele, MD, PhD
Webinar #1150v
DEBATE 3: Targeted therapies, Immunotherapies and novel chemotherapy represent a good value and are cost-effective for treating many patients with non-small cell lung cancer.
.2 hours
Roy S. Herbst, MD, PhD vs. Robert C. Doebele, MD, PhD
January 4, 2016 – January 4, 2017
Moderator: Roy S. Herbst, MD, PhD
Webinar #1150w
Expert Panel Discussion and Q&A
.2 hours
Moderator: Roy S. Herbst, MD, PhD
January 4, 2016 – January 4, 2017